34 completed, 2 recruiting, 2 terminated, 1 unknown. 40 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 40 | Completed 34, Recruiting 2, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Helminthiasis: new trials by email Literature Review of Helminthiasis trials Research Report on Helminthiasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults Trichuris trichiura Egg Inoculum - Whipworm, Trichuriasis | Phase 1 | Recruiting | George Washington University | 18 | 2025-09-10 | 2026-06-04 |
| Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets Oxantel Pamoate, Placebo - Healthy | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 45 | 2025-01-27 | 2025-08-28 |
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar rSm-p80 + GLA-SE - Schistosomiasis | Phase 1 | Completed | International Vaccine Institute | 120 | 2023-11-17 | 2026-04-29 |
| Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults Sm-p80, Sm-p80 + GLA-SE - Schistosomiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2022-05-23 | 2025-07-14 |
| PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets Oxfendazole, Placebo - Filariasis | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 30 | 2022-04-21 | 2022-12-20 |
| Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug AWZ1066S, Placebo - Filariasis, Lymphatic, Onchocerciasis | Phase 1 | Terminated | Liverpool School of Tropical Medicine | 30 | 2021-12-10 | 2023-09-21 |
| A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Moxidectin - Onchocerciasis | Phase 1 | Completed | Medicines Development for Global Health | 36 | 2021-03-29 | 2025-09-05 |
| Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Sm-TSP-2/Alhydrogel® vaccine, Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701, ENGERIX-B Hepatitis B Vaccine - Schistosomiasis, Schistosoma Mansoni | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 290 | 2019-10-07 | 2025-11-04 |
| A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults GLA-AF, Hepatitis B Virus Vaccine (Recombinant), Sm-TSP-2/Alhydrogel - Schistosomiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2018-05-20 | 2021-02-02 |
| Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults Na-GST-1, CPG 10104 - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 24 | 2018-02-01 | 2021-01-13 |
| Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside LSF emodepside (BAY 44-4400) or matching placebo - Filariasis | Phase 1 | Completed | Drugs for Neglected Diseases | 24 | 2017-11-14 | 2020-04-15 |
| Relative Bioavailability Study of Emodepside IR-tablets and Solution Emodepside (BAY 44-4400) - Filariasis | Phase 1 | Completed | Drugs for Neglected Diseases | 77 | 2017-10-26 | 2020-03-09 |
| Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers Oxfendazole - Helminthic Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2017-05-12 | 2019-12-17 |
| Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children Na-GST-1/Alhydrogel, Na-APR-1 (M74)/Alhydrogel, Hepatitis B Vaccine - Hookworm Disease, Hookworm Infection | Phase 1 | Completed | Baylor College of Medicine | 60 | 2017-01-01 | 2025-01-13 |
| Single Ascending Dose Safety Study of Oxfendazole oxfendazole, placebo - Tenia Solium Infection | Phase 1 | Withdrawn | Johns Hopkins Bloomberg School of Public Health | 2016-08-01 | 2016-08-30 | |
| Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Ivermectin, Diethylcarbamazine Albendazole (IDA) - Wuchereria Bancrofti Infection | Phase 1 | Completed | University Hospitals Cleveland Medical Center | 66 | 2016-04-17 | 2019-04-26 |
| Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) T1, T2, T3, T1,T3,T2, T2,T1,T3 - Helminthiasis | Phase 1 | Completed | Insud Pharma | 54 | 2016-03-01 | 2017-06-02 |
| Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults Na-GST-1/Alhydrogel plus GLA-AF, Na-APR-1 (M74)/Alhydrogel, Na-APR-1 (M74)/Alhydrogel plus GLA-AF - Hookworm Infection, Hookworm Disease | Phase 1 | Completed | Baylor College of Medicine | 60 | 2016-01-01 | 2019-12-03 |
| First in Man Clinical Trial of Emodepside (BAY 44-4400) emodepside (BAY 44-4400), placebo - Healthy Volunteers | Phase 1 | Completed | Drugs for Neglected Diseases | 79 | 2015-12-01 | 2020-04-13 |
Showing 20 of 40. Sign in to see all of them.
Ancylostomiasis (12) · Hookworm Infections (11) · Schistosomiasis (8) · Neglected Diseases (7) · Anemia, Iron-Deficiency (6) · Onchocerciasis (5) · Filariasis (4) · Neurocysticercosis (4) · Taeniasis (4) · Parasitic Diseases (3) · Trematode Infections (3) · Elephantiasis, Filarial (2) · Epilepsy (2) · Neuroinflammatory Diseases (2)
Infections (40) · Parasitic Diseases (37) · Nematode Infections (22) · Secernentea Infections (20) · Strongylida Infections (13) · Vector Borne Diseases (11) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Hemic and Lymphatic Diseases (8) · Trematode Infections (8) · Disease Attributes (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Spirurida Infections (7)
Bay 44-4400 (4) · oxfendazole (4) · Hepatitis B Vaccines (3) · GLA-AF adjuvant (2) · Praziquantel (2) · emodepside (2) · AIDSVAX B-E (1) · ASP-1 protein, Necator americanus (1) · Albendazole (1) · CPG-oligonucleotide (1) · D-Worm (1) · DNA (1) · Granuflex E (1) · Ivermectin (1) · Mesalamine (1)
Baylor College of Medicine (11) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Drugs for Neglected Diseases (3) · National Institute of Mental Health (NIMH) (2) · Swiss Tropical & Public Health Institute (2) · Albert B. Sabin Vaccine Institute (1) · Bayer (1) · EuroVacc Foundation (1) · George Washington University (1) · GlaxoSmithKline (1) · Insud Pharma (1) · International Vaccine Institute (1) · Johns Hopkins Bloomberg School of Public Health (1) · Liverpool School of Tropical Medicine (1) · Medicines Development for Global Health (1)
United States (12) · Brazil (5) · United Kingdom (4) · Gabon (3) · Tanzania (2) · Uganda (2) · Australia (1) · Burkina Faso (1) · China (1) · Côte d’Ivoire (1) · France (1) · Germany (1) · Ghana (1) · Madagascar (1) · Malaysia (1)
David Diemert, MD (4) · Ayola Adegnika, MD (3) · David J Diemert, MD (3) · Masahiro Fujita, M.D. (2) · Ahmed K. Al-Delaimy, MSc (1) · Alexander Loukas, PhD (1) · Daniel Paris (1) · Daniel Paris, MD, PhD (1) · Dianne Jones, BAppSc (1) · Florian Marks (1) · Frederic Monnot (1) · Gary Simon, M.D., Ph.D (1)
PMID 28464026, PMID 18396361, PMID 22633322, PMID 22802974, PMID 26571311, PMID 29346388, PMID 29749279, PMID 29780848, PMID 30745383, PMID 31107869, PMID 32816721, PMID 32926834, PMID 33188747, PMID 34310218, PMID 34597297, PMID 36996185, PMID 37262040, PMID 38513684, PMID 38924387, PMID 40707999, PMID 41121745, PMID 41285840, PMID 41662151, PMID 41705834, PMID 42848323, PMID 8615453, PMID 9364715, PMID 9840607
2015 (2), 2017 (2), 2023 (1), 5UM1AI148373-03 (1), U01AI066050 (1)